Metabolic 5 min read

Tirzepatide — The First Dual GIP / GLP-1 Agonist

An engineered 39-residue peptide that activates GIP and GLP-1 receptors with a single molecule — the first approved drug to do so, and the new benchmark for incretin pharmacology.

Tirzepatide (LY3298176) is Eli Lilly’s “twincretin” — the first approved peptide drug to deliberately activate both the GIP and GLP-1 receptors in a single, balanced molecule. The MHRA authorised it under the brand name Mounjaro for type-2 diabetes in 2022 and for chronic weight management in 2023, with NICE subsequently recommending it within the NHS specialist-weight-management pathway in 2024. In the United States it is also marketed as Zepbound for obesity. It has rapidly become the new benchmark against which every incretin analogue is measured.

The molecule's clinical story is well-documented; the more interesting question for research purposes is why dual agonism produces substantially more weight loss than the best GLP-1 alone.

What it is

Tirzepatide is a 39-amino-acid peptide built on a GIP backbone and modified with:

A C20 fatty-acid side chain at position 20 (Lys), giving albumin binding and the long half-life that supports once-weekly dosing.
Sequence substitutions tuned to give roughly full agonism at GIPR and partial agonism at GLP-1R (more on this below).

The engineering target was a single peptide that binds and activates both receptors with a controlled ratio — not just a hybrid that co-stimulates them. The "balanced agonism" framing was a deliberate design choice and shaped the pharmacology.

Mechanism: balanced, but not symmetric

Bench pharmacology (Coskun et al., 2018) shows that tirzepatide:

Acts as a full agonist at human GIPR with affinity similar to native GIP.
Acts as a partial agonist at GLP-1R, with about 1% the potency of native GLP-1 but with similar functional efficacy at saturating concentrations.

The interesting twist is that the GLP-1R partial agonism is exactly what makes the molecule tolerable. Full GLP-1R agonism (e.g. high-dose semaglutide) is limited by gastrointestinal side-effects. By "biasing" the GLP-1R signal — partial agonist behaviour, slower receptor internalisation — tirzepatide can sustain higher doses with broadly similar tolerability.

The GIP component adds:

Adipose-tissue effects that GLP-1 alone doesn't deliver. GIPR is highly expressed in white adipose tissue.
Insulin-secretagogue contribution that's complementary to GLP-1's beta-cell signal.
Central nervous system effects in hypothalamic appetite centres that are still being unpicked in 2026.

What the clinical literature shows

The SURPASS programme (type-2 diabetes) and SURMOUNT programme (obesity) collectively published more than ten phase-3 trials between 2021 and 2025. The defining numbers:

SURMOUNT-1 (Jastreboff et al., NEJM, 2022): adults with obesity, 72 weeks. Mean weight loss vs placebo: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg).
SURPASS-2 (Frias et al., NEJM, 2021): vs semaglutide 1 mg in type-2 diabetes. Tirzepatide produced larger HbA1c reductions and larger weight loss at every dose tested — the first head-to-head win against the prior GLP-1 benchmark.
SURMOUNT-2 (Garvey et al., Lancet, 2023): obesity + T2D, 72 weeks. Mean weight loss −12.8% (10 mg) and −14.7% (15 mg).
SURPASS-CVOT (cardiovascular outcomes): pre-specified non-inferiority to dulaglutide. Read-out in 2025; tirzepatide non-inferior and trending towards superiority.

The "across-trial mean" for the 15 mg dose sits around 20–22% weight loss at one year. Semaglutide 2.4 mg, by comparison, sits around 15%. Real-world data echo this.

Side effects and the discontinuation curve

The side-effect profile is dominated by gastrointestinal events (nausea, vomiting, diarrhoea, constipation) typical of GLP-1 class. Discontinuation rates for adverse events in SURMOUNT-1 ranged 4–7% across active doses — broadly comparable to semaglutide. Dose titration over 16–20 weeks is the standard mitigation.

What's notably absent from the safety signal: significant hypoglycaemia in non-diabetic populations. This is a meaningful clinical advantage for the molecule and follows from the glucose-dependent insulinotropic mechanism of both GIP and GLP-1.

What's still being unpicked

Maintenance after discontinuation. SURMOUNT-4 showed substantial weight regain over 52 weeks following tirzepatide cessation. The weight-loss is not "trained-in" — it appears to require continued exposure.
Lean-mass preservation in older adults. Body-composition sub-studies are reassuring on average but the variance is wide.
Long-term cardiovascular outcomes beyond non-inferiority. The SURPASS-CVOT signal is encouraging but full Kaplan-Meier separation will take additional years of follow-up.

Half-life and stability

The C20 fatty-acid albumin-anchor produces a human elimination half-life of approximately 5 days, supporting once-weekly subcutaneous dosing. Animal half-lives are again shorter — typically 2–3 days in rodents — because albumin biology differs across species.

Lyophilised tirzepatide is stable for years at -20 °C. After reconstitution, the prescribing-information stability is 21 days refrigerated.

Quality and supply

Subtle modifications in the peptide backbone or C-terminal amide processing change GIPR and GLP-1R affinities asymmetrically. A research-grade preparation that is missing the correct backbone modifications can look pure on HPLC but behave like a different molecule in receptor assays. Pharma Tides supplies tirzepatide at >99% HPLC purity with full ESI-MS identity confirmation on every lot; the product page lists available strengths with free tracked delivery.

Note that Mounjaro (Eli Lilly’s licensed product) is a prescription-only medicine. The research-grade tirzepatide on this site is not the same regulatory product and must only be used for in-vitro laboratory work; it cannot be prescribed, dispensed or self-administered.